Patent 12245997

Prior art

Earlier patents, publications, and products that may anticipate or render the claims unpatentable.

Active provider: Google · gemini-2.5-flash

Prior art

Earlier patents, publications, and products that may anticipate or render the claims unpatentable.

✓ Generated

To identify the most relevant prior art for US patent 12245997, I will examine the patent citations listed within the patent itself. Prior art is generally defined as information that has been made available to the public in any form before a given date that might be relevant to a patent's claims of originality. Under 35 U.S.C. § 102, an invention is not patentable if it was described in a printed publication or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.

Here's an analysis of the cited prior art for US patent 12245997:

Cited Patent References:

  1. WO2008048194A1

    • Full Citation: WO2008048194A1 - Use of the protein kinase c inhibitor tamoxifen for the treatment of bipolar disorder
    • Publication/Filing Date: Priority Date: 2006-10-20, Publication Date: 2008-04-24
    • Brief Description: This international patent application describes the use of tamoxifen, a protein kinase C (PKC) inhibitor, for the treatment of bipolar disorder. Tamoxifen is noted for demonstrating antimanic properties in humans.
    • Potential Anticipated Claims (35 U.S.C. § 102): This reference explicitly mentions the use of a PKC inhibitor (tamoxifen) for bipolar disorder. Since Endoxifen, the active ingredient in US 12245997, is also a PKC inhibitor and a metabolite of tamoxifen, this prior art could potentially anticipate claims 1 and 6, particularly regarding the underlying mechanism of action (PKC inhibition) and the general treatment of bipolar disorder with a related compound.

  2. WO2009152430A2

    • Full Citation: WO2009152430A2 - Methods of treatment of bipolar disorder
    • Publication/Filing Date: Priority Date: 2008-06-12, Publication Date: 2009-12-17
    • Brief Description: This international patent application generally discloses methods for the treatment of bipolar disorder. While the specific active agent isn't detailed from the title, its broad scope regarding bipolar disorder treatment is relevant.
    • Potential Anticipated Claims (35 U.S.C. § 102): This reference could potentially anticipate the broader concept of treating bipolar disorder (Claims 1 and 6), depending on the specific compounds and methods disclosed within its full text. Further analysis of its claims and detailed description would be needed to assess specific anticipation.

  3. US20120201908A1

    • Full Citation: US20120201908A1 - Method of treating bipolar disorder or depression using an antiestrogen
    • Publication/Filing Date: Priority Date: 2009-08-19, Publication Date: 2012-08-09
    • Brief Description: This US patent application describes methods of treating bipolar disorder or depression using an antiestrogen. Endoxifen is a selective estrogen receptor modulator (SERM) and is considered an antiestrogen.
    • Potential Anticipated Claims (35 U.S.C. § 102): This reference is highly relevant as it teaches the use of an antiestrogen for treating bipolar disorder or depression. Given that endoxifen is a SERM (a type of antiestrogen), this patent application could potentially anticipate Claims 1, 4, 5, and 6, especially regarding the use of this class of compounds for the specified conditions.

  4. WO2014141292A2

    • Full Citation: WO2014141292A2 - Endoxifen citrate polymorph and process for preparing the same
    • Publication/Filing Date: Priority Date: 2013-03-04, Publication Date: 2014-09-18
    • Brief Description: This international patent application focuses on the specific chemical form of endoxifen, namely endoxifen citrate polymorphs, and methods for their preparation. It does not directly teach a method of treatment for bipolar I disorder.
    • Potential Anticipated Claims (35 U.S.C. § 102): This reference is relevant to the composition of endoxifen citrate itself. While it doesn't directly describe the therapeutic method of US 12245997, it provides prior art for the specific chemical compound used in the claims. Therefore, it does not anticipate the method claims (1-10) of US 12245997 under 35 U.S.C. § 102, but establishes the known nature of endoxifen citrate.

  5. US9333190B2

    • Full Citation: US9333190B2 - Endoxifen compositions and methods
    • Publication/Filing Date: Priority Date: 2006-11-21, Publication Date: 2016-05-10
    • Brief Description: This patent, assigned to Jina Pharmaceuticals, Inc., discusses endoxifen compositions and methods. The full scope would need to be reviewed to determine if it covers the specific treatment parameters of US 12245997.
    • Potential Anticipated Claims (35 U.S.C. § 102): As an earlier patent by the same assignee concerning "Endoxifen compositions and methods," this could be highly relevant. Depending on its specific claims and disclosure regarding dosages, formulations (e.g., enteric coating), and treatment duration for bipolar I disorder, it could potentially anticipate any or all of claims 1-10 of US 12245997.

  6. US20190231687A1

    • Full Citation: US20190231687A1 - Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
    • Publication/Filing Date: Priority Date: 2006-11-21, Publication Date: 2019-08-01
    • Brief Description: This US patent application, also assigned to Jina Pharmaceuticals, Inc., specifically mentions endoxifen methods and compositions for treating psychiatric and neurodegenerative diseases. Bipolar I disorder falls under psychiatric diseases.
    • Potential Anticipated Claims (35 U.S.C. § 102): This reference is very closely related, as it directly addresses endoxifen for psychiatric diseases. Depending on the details of its disclosure regarding specific dosages, formulations (e.g., enteric coating), administration frequency, treatment duration, and the exclusion of rescue medication for bipolar I disorder, it could potentially anticipate any or all of claims 1-10 of US 12245997.

  7. US11291640B2

    • Full Citation: US11291640B2 - Endoxifen for the treatment of bipolar I disorder
    • Publication/Filing Date: Priority Date: 2020-04-10, Publication Date: 2022-04-05
    • Brief Description: This patent, also assigned to Jina Pharmaceuticals, Inc., has the exact same title as US 12245997 and a very similar priority date. This indicates it is likely a related patent or a family member.
    • Potential Anticipated Claims (35 U.S.C. § 102): This patent is highly likely to be a co-pending or family application and would constitute 35 U.S.C. § 102(a)(2) prior art (or pre-AIA 35 U.S.C. 102(e)) if it names a different inventive entity and was effectively filed before the effective filing date of the claimed invention in US 12245997. Given the identical title and assignee, it is possible there are overlapping inventors. If the inventors are identical, it generally would not be considered "by another" for purposes of prior art. However, without a detailed comparison of the claims and specifications, it's difficult to definitively state which specific claims are anticipated. The fact that it has the same title and covers the same subject matter strongly suggests it anticipates or makes obvious the claims of US 12245997, unless there are subtle, patentable distinctions in the specific methods or formulations claimed.

Cited Family Cites Families:

  1. CA3145867A1
    • Full Citation: CA3145867A1 - Sustained release compositions of endoxifen
    • Publication/Filing Date: Priority Date: 2019-07-03, Publication Date: 2021-01-07
    • Brief Description: This Canadian patent application describes sustained-release compositions of endoxifen.
    • Potential Anticipated Claims (35 U.S.C. § 102): While US 12245997 specifies an enteric coated tablet for once-daily administration, this reference to "sustained release compositions of endoxifen" could potentially overlap with the enteric coating aspect if an enteric coating is considered a form of sustained release. If the sustained-release compositions disclosed in CA3145867A1 inherently achieve the "once per day" administration and therapeutically effective concentration without rescue medication for bipolar I disorder, it could anticipate elements of claims 1 and 6 regarding the formulation.

Conclusion on Most Relevant Prior Art:

The most relevant prior art references appear to be:

  • US11291640B2: With the exact same title ("Endoxifen for the treatment of bipolar I disorder") and a very close priority date, this patent is almost certainly the most directly relevant prior art. A detailed comparison of the claims of US11291640B2 against US 12245997 is crucial to determine anticipation or obviousness.
  • US20190231687A1: This patent application by the same assignee explicitly mentions "Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases," which directly encompasses bipolar I disorder. Its detailed disclosure would be highly pertinent.
  • US9333190B2: Another patent from the same assignee, "Endoxifen compositions and methods," would require careful examination to see if its scope includes the specific treatment regimen for bipolar I disorder claimed in US 12245997.
  • US20120201908A1: This reference's teaching of using an antiestrogen for bipolar disorder is particularly relevant given endoxifen's classification as a SERM/antiestrogen.

These patents and applications directly address endoxifen, its compositions, or its use in treating psychiatric conditions including bipolar disorder, making them strong candidates for anticipating or rendering obvious the claims of US 12245997 under 35 U.S.C. § 102 (novelty) or § 103 (obviousness). The "up to 21 days" vs. "at least 21 days" duration also warrants close examination to see if it provides a patentable distinction.

Generated 5/27/2026, 6:46:35 PM